文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

重组人可溶性血栓调节蛋白对脓毒症相关凝血病患者死亡率的影响:SCARLET随机临床试验

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

SCARLET是一项在26国159个ICU开展的随机双盲安慰剂对照3期试验,纳入脓毒症相关凝血病合并心血管和/或呼吸衰竭的成人患者,比较重组人血栓调节蛋白与安慰剂对28天全因死亡率的影响。结果显示两组28天全因死亡率无统计学显著差异(26.8% vs 29.4%,P=0.32),绝对风险差2.55%(95%CI -3.68%至8.77%)。

要点

  • 重组人血栓调节蛋白组28天全因死亡率为26.8%,安慰剂组为29.4%,差异无统计学意义(P=0.32)。
  • 绝对风险差为2.55%(95%CI -3.68%至8.77%)。
  • 严重大出血不良事件发生率血栓调节蛋白组为5.8%,安慰剂组为4.0%。

核心结论

  • 在脓毒症相关凝血病患者中,与安慰剂相比,给予重组人血栓调节蛋白未显著降低28天全因死亡率。

研究设计与样本

  • SCARLET试验是一项随机、双盲、安慰剂对照、多国、多中心3期研究,在26个国家159个中心的ICU开展。
  • 纳入2012年10月至2018年3月期间入住参与ICU的成人脓毒症相关凝血病合并心血管和/或呼吸衰竭患者,凝血病定义为国际标准化比值大于1.40且无其他已知病因,血小板计数30至150×10⁹/L或24小时内血小板计数下降超过30%。
  • 共随机816例患者,800例完成研究并纳入全分析集(平均年龄60.7岁,男性437例[54.6%]),血栓调节蛋白组395例、安慰剂组405例。
  • 干预为静脉推注或15分钟输注血栓调节蛋白0.06 mg/kg/d(最大6 mg/d)或匹配安慰剂,每日一次,共6天。
  • 末次随访日期为2019年2月28日。

主要发现

  • 28天全因死亡率血栓调节蛋白组为106/395例(26.8%),安慰剂组为119/405例(29.4%),差异无统计学意义(P=0.32)。
  • 绝对风险差为2.55%(95%CI -3.68%至8.77%)。
  • 严重大出血不良事件(定义为任何颅内出血、危及生命的出血,或研究者判定为严重且连续2天输注至少1440 mL[通常6单位]浓缩红细胞的出血事件)发生率血栓调节蛋白组为23/396例(5.8%),安慰剂组为16/404例(4.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy. OBJECTIVE: To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy. DESIGN, SETTING, AND PARTICIPANTS: The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019. INTERVENTIONS: Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06 mg/kg/d [maximum, 6 mg/d]; n = 395) or matching placebo (n = 405) once daily for 6 days. MAIN OUTCOME AND MEASURES: The primary end point was 28-day all-cause mortality. RESULTS: Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P = .32). The absolute risk difference was 2.55% (95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440 mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01598831.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019. PMID: 31104069. doi:10.1001/jama.2019.5358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。